Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Building up on previous publications for type I, II, IIIa, and IIIb Lipid-based formulations (LBFs), the supersaturation potential for cinnarizine in type IV LBFs and the effect of supersaturation, lipid digestion, and precipitation inhibition in vivo was investigated. The supersaturation potential for cinnarizine-loaded type IV LBFs was high and this was investigated in vivo in rats. Supersaturated LBFs tended to show higher drug exposures in vivo than their non-supersaturated counterparts (22 - 92 % increase in AUC, not dose-normalized), but this was only statistically significant for the formulation containing a precipitation inhibitor under lipase-inhibited conditions, so the overall impact was limited. Soluplus® as a precipitation inhibitor did not increase drug exposure in general, even though the administered cinnarizine dose was higher for the supersaturated formulations. Lipase inhibition had no impact on cinnarizine absorption, indicating no increased precipitation during digestion. The results were in line with previous findings from type IIIb LBFs that revealed that the digestion process was less important for drug absorption from hydrophilic types of LBFs as opposed to the more lipophilic type I- and II systems.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijpharm.2025.125725 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipidic nanocarriers for the treatment of schizophrenia: progress and prospects of solid lipid nanoparticles and nanostructured lipid carriers.
J Biomater Sci Polym Ed
September 2025
LJ Institute of Pharmacy, Department of Pharmaceutical Technology, LJK University, Ahmedabad, India.
Schizophrenia is a persistent and incapacitating neuropsychiatric condition that presents considerable obstacles regarding pharmacological administration and therapeutic effectiveness. Lipidic nanocarriers, including Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs), have emerged as effective drug delivery vehicles for enhancing the bioavailability, stability, and controlled release of antipsychotic medicines. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) have several benefits, such as improved drug loading capacity, less systemic adverse effects, and superior efficacy in traversing the blood-brain barrier compared to conventional formulations.
View Article and Find Full Text PDFNovel development of lipid-based formulations: Improved wettability and homogeneous API solid dispersion visualised via near-infrared hyperspectral imaging.
Eur J Pharm Biopharm
September 2025
Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria; University of Graz, Institute of Pharmaceutical Sciences, Department of Pharmaceutical, Technology and Biopharmacy, Graz, Austria. Electronic address:
Lipid-based formulations have been successfully applied to improve the aqueous solubility of active pharmaceutical ingredients (APIs), however, with the bottleneck of limited wettability of the system. In this study, a lipid-based system was developed using polyglycerol ester of fatty acids (PGFA) as the main component and hexaglycerol (PG6) as a wetting agent. Felodipine, a BCS class II compound was selected as a model API.
View Article and Find Full Text PDFAdvances in Lipid-Based Nanomedicine: Pathway Specific siRNA Therapy and Optimizing Delivery for Hepatocellular Carcinoma.
Int J Nanomedicine
September 2025
Department of Pharmaceutics, Crescent School of Pharmacy, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai, Tamilnadu, India.
Hepatocellular carcinoma (HCC) is a major global health issue, ranking as the sixth most common cancer and a leading cause of cancer-related deaths worldwide. Risk factors for HCC include chronic hepatitis B and C, obesity, alcohol abuse, diabetes, and metabolic disorders. Current treatments, such as surgery, transplantation, and chemotherapy, are often ineffective in advanced stages due to tumor resistance and the inability to target key oncogenic pathways.
View Article and Find Full Text PDFCurrent status of Liraglutide delivery systems for the management of type 2 diabetes mellitus.
Drug Deliv Transl Res
September 2025
Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan, 333031, India.
Diabetes is a metabolic disorder of increasing global concern. Characterized by constantly elevated levels of glucose, severe β-cell dysfunction, and insulin resistance, it is the cause of a major burden on patients if not managed with therapeutic and lifestyle changes. The human body is slowly developing tolerance to many marketed antidiabetic drugs and the quest for the discovery of newer molecules continues.
View Article and Find Full Text PDFPrevention of Atopic Dermatitis in High-Risk Infants: A Review of the Role of Lipid-Based Barrier Repair Therapy.
Pediatr Dermatol
September 2025
James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA.
Background/objective: Growing evidence highlights the role of physiological lipids, namely ceramides, cholesterol, and free fatty acids, in maintaining skin barrier function and preventing atopic dermatitis (AD). Current evidence on the efficacy, safety, and clinical relevance of stratum corneum (SC) lipid-based therapies to prevent AD and increase skin barrier integrity in high-risk infants was reviewed and synthesized.
Methods: Searches with key words lipid-based therapy, atopic dermatitis, infant, and prevention were conducted to identify papers using PubMed, Embase, Cochrane Library, and Scopus databases from January 2000 to June 2024.